Compare Ginkgo Bioworks Holdings Inc (DNA) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.09 (market cap $763.64M), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $6.94B). The key difference: Invesco S&P 500 Low Volatility ETF is far larger — about 9.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| DNA | SPLV | |
|---|---|---|
Market Cap | $763.64M | $6.94B |
Volume | 3,204,177 | 1,663,703 |
Sector | Health | — |
52-Week High | $15.83 | $77.97 |
52-Week Low | $5.48 | $70.30 |
Typical Hold Time | 7 Days | 123 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
SPLV trades at $71.22, down 0.71% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key resistance at $72. Recent news highlights sector overweights in Utilities and Real Estate as headwinds, with the fund lagging the S&P 500's performance. Dividend payments of $0.14 are scheduled for July and September 2026.
Outlook remains cautious due to technical weakness and unappealing growth-adjusted valuation. Risks include concentrated sector exposure and macroeconomic pressures. The fund's low-volatility strategy may appeal during market uncertainty, but current technicals suggest limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
